GUARNOTTA, Valentina
 Distribuzione geografica
Continente #
NA - Nord America 8.239
EU - Europa 4.720
AS - Asia 4.450
SA - Sud America 814
AF - Africa 134
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 4
Totale 18.370
Nazione #
US - Stati Uniti d'America 8.116
SG - Singapore 1.612
IT - Italia 1.234
RU - Federazione Russa 1.224
CN - Cina 1.113
BR - Brasile 625
HK - Hong Kong 494
DE - Germania 463
VN - Vietnam 444
FI - Finlandia 411
PL - Polonia 314
FR - Francia 274
GB - Regno Unito 194
IE - Irlanda 157
UA - Ucraina 145
BD - Bangladesh 138
JP - Giappone 134
KR - Corea 93
IN - India 84
SE - Svezia 71
TR - Turchia 70
AR - Argentina 63
IQ - Iraq 53
NL - Olanda 53
MX - Messico 51
AT - Austria 40
CA - Canada 36
ZA - Sudafrica 35
BE - Belgio 32
EC - Ecuador 28
MA - Marocco 28
CO - Colombia 24
UZ - Uzbekistan 24
RO - Romania 23
CL - Cile 19
ES - Italia 19
KE - Kenya 19
PK - Pakistan 19
NP - Nepal 18
SA - Arabia Saudita 18
VE - Venezuela 18
CI - Costa d'Avorio 16
TN - Tunisia 15
PE - Perù 14
AE - Emirati Arabi Uniti 13
GR - Grecia 13
ID - Indonesia 13
PH - Filippine 13
IR - Iran 12
MY - Malesia 12
PY - Paraguay 12
CH - Svizzera 9
JO - Giordania 9
LT - Lituania 9
AU - Australia 8
AZ - Azerbaigian 7
BO - Bolivia 7
CR - Costa Rica 7
DK - Danimarca 7
KZ - Kazakistan 7
DZ - Algeria 6
EG - Egitto 6
JM - Giamaica 6
SY - Repubblica araba siriana 6
TW - Taiwan 6
AL - Albania 5
CZ - Repubblica Ceca 5
HR - Croazia 5
IL - Israele 5
TH - Thailandia 5
DO - Repubblica Dominicana 4
HN - Honduras 4
KG - Kirghizistan 4
UY - Uruguay 4
GT - Guatemala 3
KH - Cambogia 3
LB - Libano 3
MK - Macedonia 3
PR - Porto Rico 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BB - Barbados 2
BG - Bulgaria 2
BH - Bahrain 2
BS - Bahamas 2
ET - Etiopia 2
GE - Georgia 2
KW - Kuwait 2
LK - Sri Lanka 2
MD - Moldavia 2
OM - Oman 2
PS - Palestinian Territory 2
TG - Togo 2
TT - Trinidad e Tobago 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CY - Cipro 1
Totale 18.355
Città #
Singapore 997
Ashburn 959
Fairfield 886
San Jose 531
Houston 486
Hong Kong 478
Woodbridge 446
Chandler 393
Seattle 382
Wilmington 379
Council Bluffs 309
Cambridge 278
Zgierz 270
Ann Arbor 249
Moscow 206
Palermo 202
Beijing 188
Medford 160
Dublin 153
Helsinki 149
Ho Chi Minh City 143
Lauterbourg 131
Tokyo 131
Munich 117
Hanoi 113
New York 113
Los Angeles 107
Dallas 99
Des Moines 99
Princeton 99
Altamura 96
Santa Clara 93
Nanjing 91
Boardman 78
Hefei 71
Jacksonville 70
Frankfurt am Main 67
Chicago 65
Lawrence 63
San Diego 56
Milan 55
São Paulo 52
Rome 50
Ludwigshafen am Rhein 48
Buffalo 45
The Dalles 45
London 44
Dearborn 43
Izmir 39
Jinan 36
Nanchang 35
Changsha 34
Phoenix 34
Orem 32
Shenyang 32
Brussels 31
Lappeenranta 31
Tianjin 31
Nuremberg 30
Hebei 28
Rio de Janeiro 28
Tulsa 27
Ningbo 25
Baghdad 24
Columbus 24
Da Nang 24
Guangzhou 24
Jiaxing 24
Warsaw 24
Atlanta 23
Redwood City 23
Amsterdam 20
Falls Church 18
Zhengzhou 18
Chennai 17
Hangzhou 17
Johannesburg 17
Tashkent 17
Abidjan 16
Nairobi 16
Salt Lake City 16
Seoul 16
Shanghai 16
Vienna 16
Denver 15
Haiphong 15
Bucheon-si 14
Montreal 14
Paris 14
Saint Petersburg 14
Brasília 13
Casablanca 13
Naples 13
Quito 13
San Paolo di Civitate 13
Brooklyn 12
Curitiba 12
Haikou 12
Kumar 12
Pune 12
Totale 11.479
Nome #
The Daily Consumption of Cola Can Determine Hypocalcemia: A Case Report of Postsurgical Hypoparathyroidism-Related Hypocalcemia Refractory to Supplemental Therapy with High Doses of Oral Calcium 398
COLORECTAL CANCER IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A SINGLE-CENTRE EXPERIENCE. 377
Valutazione dell’insulino-sensibilità tramite clamp euglicemico iperinsulinemico in bambini in terapia sostitutiva con GH. 351
Predictors of microvascular complications in type 1 diabetic patients at onset: The role of metabolic memory 327
Superior mesenteric artery syndrome: Clinical, endoscopic, and radiological findings 282
Hepatic steatosis index in acromegaly: Correlation with insulin resistance regardless of the disease control 249
NANOG plays a hierarchical role in the transcription network regulating the pluripotency and plasticity of adipose tissue-derived stem cells 243
Development of a fuzzy expert system for the control of glycemia in type 1 diabetic patients 242
Anti-Inflammatory Action of Heterogeneous Nuclear Ribonucleoprotein A2/B1 in Patients with Autoimmune Endocrine Disorders 242
Clinical and hormonal characteristics in heterozygote carriers of congenital adrenal hyperplasia 232
Comparison between euglycemic hyperinsulinemic clamp and surrogate indices of insulin sensitivity in children with growth hormone deficiency 228
Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations during the follow-up: causal or casual association? 228
The degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome 222
Circulating Irisin Levels in Children with GH Deficiency before and after 1 Year of GH Treatment 219
Body composition assessment for the definition of cardiometabolic risk. 216
Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency 212
Correlation between adrenal function, growth hormone secretion, and insulin sensitivity in children with idiopathic growth hormone deficiency 211
Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syndrome (MU-PCOS): a comparative analysis of four simple methods useful for metabolic assessment. 205
Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. 201
Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal-Dystrophy (APECED) in Sicily: confirmation that R203X is the peculiar AIRE gene mutation. 198
Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients. 197
Extracellular vesicles as a novel immunotherapeutic strategy in hashimoto’s thyroiditis: advances in targeted delivery technologies 196
The metabolic outcomes of growth hormone treatment in children are gender specific 196
Relationship between body fat distribution and blood disorders in patients with visceral obesity with and without diabetes mellitus 193
The treatment of hyperinsulinemic hypoglycaemia in adults: an update 187
Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing's disease 186
Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis 185
Is diabetes in Cushing's syndrome only a consequence of hypercortisolism? 184
Circulating Irisin Levels as a Marker of Osteosarcopenic-Obesity in Cushing’s Disease 184
COVID-19 and the Pancreas: A Narrative Review 183
The visceral adiposity index is associated with insulin sensitivity and IGF-I levels in adults with growth hormone deficiency 183
Growth hormone and hematopoiesis: A retrospective analysis on a large cohort of children with growth hormone deficiency 183
Insulin sensitivity and secretion and adipokine profile in patients with Cushing’s disease treated with pasireotide 183
Resistin, visfatin, leptin and omentin are differently related to hormonal and metabolic parameters in growth hormone-deficient children 179
NEW THERAPEUTIC PERSPECTIVES IN IRRITABLE BOWEL SYNDROME: TARGETING LOW-GRADE INFLAMMATION, IMMUNO-NEUROENDOCRINE AXIS, MOTILITY, SDECRETION AND BEYOND 176
Correlation between Severity of Growth Hormone Deficiency and Thyroid Metabolism and Effects of Long-Term Growth Hormone Treatment on Thyroid Function in Children with Idiopathic Growth Hormone Deficiency. 174
No phenotypic differences for polycystic ovary syndrome (PCOS) between women with and without type 1 diabetes mellitus. 172
Sviluppo di un sistema di supporto decisionale tipo Fuzzy per il controllo della glicemia post-prandiale nel diabete mellito tipo 1 171
Efficacy and safety of everolimus in extrapancreatic neuroendocrine tumor: A comprehensive review of literature 170
Alta prevalenza di Sindrome dell’ovaio policistico in donne diabetiche di tipo 1 in età fertile. 168
Alte dosi di cabergolina migliorano i parametri metabolici in pazienti affetti da prolattinoma. 168
The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence” 166
Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions 166
Impact of atorvastatin plus n-3 PUFA on metabolic, inflammatory and coagulative parameters in metabolic syndrome without and with type 2 diabetes mellitus 165
Higher cardiometabolic risk in idiopathic versus autoimmune type 1 diabetes: A retrospective analysis 163
Circulating adipokine levels in diabetic patients with Cushing disease on pasireotide treatment compared with patients with type 2 diabetes mellitus 162
Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report 157
Utilizzo del Visceral Adiposity Index per l’identificazione di donne con sindrome iperandrogenica a rischio cardiometabolico. 152
Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study 152
CONVENTIONAL GLUCOCORTICOID REPLACEMENT THERAPY VS. DUAL-RELEASE HYDROCORTISONE: EFFECTS ON INFLAMMATION AND IMMUNE PROFILE IN PATIENTS WITH PRIMARY ADRENAL INSUFFICIENCY AND IMPLICATIONS OF THERAPY RESPONSE PREDICTORS 151
Effetti a lungo termine del trattamento con Simvastatina ed Ezetimibe sui livelli di HDL-C e hs-PCR in pazienti affetti da Ipercolesterolemia familare(FH) con pregresso IMA e/o Lesione carotidea 151
The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma? 151
Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia 150
Efficacia della associazione Atorvastatina e n-3 PUFA in pazienti affetti da dislipidemia combinata e ad alto rischio di eventi cardiovascolari 148
EFFECTS OF PASIREOTIDE TREATMENT ON CARDIOMETABOLIC RISK IN PATIENTS WITH CUSHING’S DISEASE : AN ITALIAN, MULTICENTER STUDY 147
Comparison of clinical and metabolic effects of pasireotide and pituitary surgery in Cushing disease 146
Off-line control of the postprandial glycemia in type 1 diabetes patients by a fuzzy logic decision support 144
Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group 142
Maggiore rischio cardiometabolico in pazienti di razza non caucasica affetti da diabete mellito di tipo 1 idiopatico rispetto alla forma autoimmune in pazienti caucasici. 139
The adipose visceral dysfunction plays an important role in diabetes in Cushing disease. 136
Insulin sensitivity and visceral adiposity index (VAI) in women with functional secondary amenorrhea. 133
Clinical and metabolic impact of three-times-weekly versus daily growth hormone (GH) treatment in naïve GH-deficient children 133
Improved cardiovascular and cardiometabolic risk in patients with type 1 diabetes and autoimmune polyglandular syndrome switched from glargine to degludec due to hypoglycaemic variability 131
Miglioramento clinico e metabolico in pazienti affetti da diabete mellito tipo 1 associato ad altre endocrinopatie (APS) dopo shift della terapia insulinica basale con glargine a degludec 130
IL CONSUMO DI BEVANDE RICCHE DI ACIDO ORTOFOSFORICO COME FATTORE DI RISCHIO PER LO SVILUPPO DI IPOCALCEMIA: IL CASO DI UNA DONNA CON IPOPARATIROIDISMO POST-CHIRURGICO 128
Effects of osilodrostat and metyrapone on 2D and 3D models of adrenocortical carcinoma cell lines viability: preliminary results 128
GH-treatment improves growth and reduces the severity of fibrosis and hypertansaminasemia in a prepubertal child with sclerosant cholangiopathy 126
Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing’s disease 124
Impact of Chemical Endocrine Disruptors and Hormone Modulators on the Endocrine System 123
Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: A real-life study 122
Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia, severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations in acromegaly due to a therapeutically resistant pituitary GH-secreting macroadenoma 121
IPOVITAMINOSI D ED EFFETTI BENEFICI DELLA TERAPIA SOSTITUTIVA CON GH SUI LIVELLI DI VITAMINA D IN BAMBINI AFFETTI DA DEFICIT DI GH 121
Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily. 115
Traitement séquential avec des corticostéroides dans les ophtalmopathy Graves 114
Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers. 114
More favorable metabolic impact of three-times-weekly versus daily growth hormone (GH) treatment in naïve GH-deficient children 113
Influence of the Microbiota Through the Gut-Brain Axis in Neurological Diseases 112
Ultrasound Parameters Can Accurately Predict the Risk of Malignancy in Patients with "Indeterminate TIR3b" Cytology Nodules: A Prospective Study 112
Poor diagnostic value of the euglycemic-hyperinsulinemic clamp in the clinical assessment of insulin resistant women with PCOS. 112
Effects of the ketogenic diet compared to the mediterranean diet in patients with acromegaly 112
Correction to: One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus 111
ENDOCRINE TUMOURS: Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus. 111
Evidence of greater severity of diabetic foot ulcers during COVID-19 pandemic: A real-life single-centre cohort study 110
Modificazioni di insulino-secrezione, insulino-sensibilità e funzione adiposa durante terapia con pasireotide in un gruppo di pazienti con malattia di Cushing 110
Miglioramento dell'insulino-sensibilità e dell'insulino-secrezione dopo switch da terapia con glucocorticoidi tradizionali a idrocortisone "dual release" in pazienti affetti da iposurrenalismo 109
Predictive factors of polycystic ovary syndrome in girls with precocious pubarche 109
Maggior rischio cardiometabolico nelle donne affette da Cushing, anche in assenza di una franca Sindrome Metabolica. 108
Cabozantinib in the Treatment of Neuroendocrine Neoplasms: Insights across Different Tumor Origins 107
Glucocorticoid excess and COVID-19 disease 106
Levothyroxine and insulin requirement in autoimmune polyglandular type 3 syndrome: a real-life study 105
Adrenal Cushing’s syndrome in children 104
LONG-TERM METABOLIC EFFECTS OF GH THERAPY IN CHILDREN WITH IDIOPATHIC GH DEFICIENCY 104
EFFECT OF SWITCH FROM CONVENTIONAL GLUCOCORTICOIDS TO “DUAL RELEASE HYDROCORTISONE” (DR-HC) ON METABOLIC PROFILE AND QUALITY OF LIFE IN ADULT PATIENTS WITH SECONDARY ADRENAL INSUFFICIENCY (SAI): RESULTS OF THREE MONTHS FOLLOW-UP 103
INSULIN SECRETION AND SENSITIVITY DURING PASIREOTIDE TREATMENT IN PATIENTS WITH RECURRENT CUSHING DISEASE: A CASE SERIES 102
Valutazione dell’insulino-sensibilità e della funzione adiposa viscerale nel diabete mellito tipo 1 autoimmune ed idiopatico. 101
GENOMIC AND PROTEOMIC EVALUATION OF VISCERAL AND SUBCUTANEOUS ADIPOSE DERIVED STEM CELLS AND FUNCTIONAL ROLES OF PLURIPOTENCY TRANSCRIPTION FACTORS 98
Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus 98
Very Low-Calorie Ketogenic Diet: A Potential Application in the Treatment of Hypercortisolism Comorbidities 95
Irisin: A Possible Marker of Adipose Tissue Dysfunction in Obesity 95
Diabetic foot ulcers: Retrospective comparative analysis from Sicily between two eras 95
Totale 16.294
Categoria #
all - tutte 68.703
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.703


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021127 0 0 0 0 0 0 0 0 0 0 0 127
2021/20221.166 39 168 41 62 45 59 46 65 199 161 55 226
2022/20231.357 146 261 22 122 139 190 75 110 188 8 62 34
2023/2024710 26 98 27 64 53 167 102 49 10 26 17 71
2024/20252.393 68 126 132 201 52 99 159 243 185 244 269 615
2025/20267.973 511 266 521 704 671 1.110 1.296 866 674 774 452 128
Totale 19.200